News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant Pharmaceuticals International's (VRX) Zelapar "Approvable" By FDA


10/19/2005 5:13:17 PM

COSTA MESA, Calif.--(BUSINESS WIRE)--Oct. 4, 2005--Valeant Pharmaceuticals International (NYSE:VRX) today announced that the company received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zelapar(TM) (selegiline hydrochloride). The approvable letter requests additional clarification on specific issues previously addressed by Valeant. Valeant plans to meet with the FDA, promptly as they have requested, to discuss and resolve these matters.

Read at Reuters
Read at AP
Read at BioSpace.com


comments powered by Disqus
Reuters
AP
BioSpace.com
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES